ASCO 2023 | INDIGO: clinical benefit of vorasidenib in patients with grade 2 IDH-mutant glioma

Karan Dixit, MD, Northwestern Memorial Hospital, Chicago, IL, discusses the Phase III INDIGO trial (NCT04164901), which evaluated the efficacy and safety of vorasidenib, a dual inhibitor of mutant IDH1/2 enzymes, in patients with grade 2 gliomas. Patients were randomized to receive vorasidenib or placebo, and the primary endpoint was radiographic progression-free survival (PFS) assessed by an independent radiology committee. Secondary endpoint was time to next intervention (TTNI). PFS and TTNI was also significantly improved in the vorasidenib arm, and adverse events were manageable. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.